Basel, 7 May 2026 - BioCopy SA, a Swiss-German biopharmaceutical company headquartered in Basel, has announced the closing of the first CHF 9 million tranche of its Series A financing round. The proceeds will fund IND-enabling studies for the company's lead lung cancer candidate, which is now entering preclinical development. The first-in-human Phase 1 trial is targeted for the fourth quarter of 2027.
[...]
This is an abstract of the document. To keep reading, click here and get access to the original version.